Zhejiang Xianju Pharmaceutical Co Ltd Total Liabilities
Zhejiang Xianju Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Zhejiang Xianju Pharmaceutical Co Ltd (002332) has total liabilities worth CN¥1.14 Billion CNY (≈ $167.22 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002332 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zhejiang Xianju Pharmaceutical Co Ltd (2006–2025)
Total liabilities of Zhejiang Xianju Pharmaceutical Co Ltd from 2006 to 2025. This chart illustrates how Zhejiang Xianju Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Zhejiang Xianju Pharmaceutical Co Ltd (002332) investment intensity to see how much of total assets are deployed in long-term investments.
Zhejiang Xianju Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Xianju Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Centuria Industrial REIT
AU:CIP
|
Australia | AU$1.46 Billion |
|
Shenzhen Rongda Photosensitive & Technology Co Ltd
SHE:300576
|
China | CN¥375.29 Million |
|
Altus Group Limited
TO:AIF
|
Canada | CA$537.21 Million |
|
Upwork Inc
NASDAQ:UPWK
|
USA | $669.26 Million |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
China | CN¥701.92 Million |
|
Lotte Rental Co Ltd
KO:089860
|
Korea | ₩6.47 Trillion |
|
Shanghai Weaver Network Co Ltd
SHG:603039
|
China | CN¥1.62 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $92.95 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Zhejiang Xianju Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zhejiang Xianju Pharmaceutical Co Ltd total assets.
Liquidity & Leverage Metrics
Zhejiang Xianju Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Zhejiang Xianju Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Xianju Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Xianju Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Zhejiang Xianju Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.18 Billion ≈ $172.20 Million |
+5.88% |
| 2024-12-31 | CN¥1.11 Billion ≈ $162.64 Million |
-4.42% |
| 2023-12-31 | CN¥1.16 Billion ≈ $170.15 Million |
-5.52% |
| 2022-12-31 | CN¥1.23 Billion ≈ $180.09 Million |
-30.79% |
| 2021-12-31 | CN¥1.78 Billion ≈ $260.22 Million |
-21.17% |
| 2020-12-31 | CN¥2.26 Billion ≈ $330.11 Million |
-18.43% |
| 2019-12-31 | CN¥2.77 Billion ≈ $404.72 Million |
+1.20% |
| 2018-12-31 | CN¥2.73 Billion ≈ $399.92 Million |
-0.57% |
| 2017-12-31 | CN¥2.75 Billion ≈ $402.21 Million |
+98.64% |
| 2016-12-31 | CN¥1.38 Billion ≈ $202.48 Million |
+7.56% |
| 2015-12-31 | CN¥1.29 Billion ≈ $188.24 Million |
-18.30% |
| 2014-12-31 | CN¥1.57 Billion ≈ $230.42 Million |
+0.18% |
| 2013-12-31 | CN¥1.57 Billion ≈ $230.00 Million |
+26.72% |
| 2012-12-31 | CN¥1.24 Billion ≈ $181.51 Million |
+44.23% |
| 2011-12-31 | CN¥860.02 Million ≈ $125.85 Million |
+22.63% |
| 2010-12-31 | CN¥701.29 Million ≈ $102.62 Million |
-9.89% |
| 2009-12-31 | CN¥778.28 Million ≈ $113.89 Million |
+4.13% |
| 2008-12-31 | CN¥747.44 Million ≈ $109.37 Million |
+15.98% |
| 2007-12-31 | CN¥644.44 Million ≈ $94.30 Million |
+8.61% |
| 2006-12-31 | CN¥593.35 Million ≈ $86.83 Million |
-- |
About Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progestero… Read more